Form 4: Syros Pharmaceuticals Director Sells 134,713 Shares

A Syros Pharmaceuticals director, Nancy A. Simonian, sold 134,713 shares of common stock at a weighted average price of $0.2653.

Summary

• Nancy A. Simonian, a director at Syros Pharmaceuticals, sold 134,713 shares of common stock on November 25, 2024.
• The shares were sold at a weighted average price of $0.2653 per share.
• The transactions occurred at prices ranging from $0.2604 to $0.2723.
• Following the sale, Ms. Simonian directly owns 41,070 shares of Syros Pharmaceuticals stock.

Sentiment

Score: 4

Explanation: The document is neutral in nature, reporting a stock sale by a director. While not inherently negative, such sales can sometimes be viewed with caution by investors.

Negatives

• A director selling a significant number of shares could be perceived negatively by the market.

Risks

• Large sales by insiders can sometimes indicate a lack of confidence in the company's future prospects.
• The market may react negatively to the sale, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in the pharmaceutical industry, and this transaction is a routine disclosure of a director's stock sale.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, and this transaction is consistent with regulatory requirements.
• Sales by directors are not uncommon, and the impact on the stock price will depend on market sentiment and other factors.

Stakeholder Impact

• Shareholders may react to the news of the director's stock sale, potentially impacting the stock price.

Key Dates

Keywords

Syros Pharmaceuticals, insider trading, stock sale, Form 4, director, Nancy A. Simonian, SYRS